BioCorRx BICX
OTC BICX
$0.20 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

BioCorRx (BICX) Gains (Losses) on Sale of Assets & Investments (2019)

Updated

BioCorRx's Non Operating Investment Income came in at $3,804 for Q4 2019.

Analysis

BioCorRx (BICX) Gains (Losses) on Sale of Assets & Investments (2019) Analysis & Trends

For FY2019, BioCorRx's Non Operating Investment Income was $1,902.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 BioCorRx 830.00 -906,148.00 -56,997.00 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 3,804.00
Sep 30, 2019 -1,902.00
API Access

BioCorRx Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=BICX&period=max&api_key=YOUR_API_KEY